Charlotte blood cancer advocate David Wallace shares lessons from six years with undetectable disease ahead of Blood Cancer Awareness Month.
CHARLOTTE, NC, UNITED STATES, August 11, 2026 /EINPresswire.com/ — PV Reporter has unveiled a patient-focused educational guide that documents how its founder, David Wallace, achieved complete molecular remission from polycythemia vera (PV), a rare blood cancer. The release comes just before September’s Blood Cancer Awareness Month and equips patients with information to talk with their doctors about driver mutations, treatment objectives, and care from MPN specialists.
The guide can be accessed at https://pvreporter.com/polycythemia-vera-molecular-remission/.
Wallace received his PV diagnosis in 2009. Today, his blood counts are within normal range, and the JAK2 mutation responsible for his illness has been undetectable for over six years. His JAK2 V617F allele burden dropped from roughly 28 percent to an undetectable level—a state known as complete molecular remission. Remission does not equal a cure, and patient outcomes with treatment differ widely.
This new resource outlines Wallace’s journey from phlebotomy through pegylated interferon and ultimately to a combination therapy with ruxolitinib. It also describes how research he came across while attending the 2015 American Society of Hematology annual meeting prompted him to bring up the combination with his doctor. During his treatment, Wallace developed skin cancer that requires ongoing monitoring, experienced infections, and went through multiple dose adjustments. He continues on a low-dose maintenance regimen.
In the early years of his PV journey, Wallace consulted five different hematologists as he searched broadly for a physician with deep MPN knowledge and a willingness to engage with current studies. His changes in doctors reflected a wider quest for informed medical care and were not directly tied to combination therapy. After asking the chief of hematology at his cancer center for “a doctor who knows more about PV than I do,” he was directed to the specialist who still treats him today.
“Most PV patients are never told that deep remission is even on the table,” Wallace said. “Newly diagnosed patients must learn about their illness, understand what each treatment is intended to accomplish and make sure they are seeing a true MPN specialist.”
Published studies indicate that deep molecular responses can be achieved with pegylated interferon alone or in combination with ruxolitinib, though results vary and complete molecular remission remains rare. The guide also points patients to PV Reporter’s free, doctor-reviewed MPN Specialist Locator at https://pvreporter.com/mpn-specialists-cancer-treatment-centers/.
About PV Reporter
PV Reporter was founded by David Wallace in 2013 to offer patient-friendly information on myeloproliferative neoplasms. The site publishes emerging MPN research and maintains a doctor-reviewed specialist locator alongside a free clinical trial finder. Through PV Reporter and the nonprofit MPN Cancer Connection, Wallace has supported thousands of patients and caregivers around the globe.
David Wallace
PV Reporter
+1 704-323-6771
david@pvreporter.com
